Microbio Co Ltd   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Taipei Taiwan (2000)

Organization Overview

First Clinical Trial
2008
NCT00707681
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Fountain Biopharma Inc. | Microbio Co Ltd | Microbio Shanghai Co., Ltd. | Oneness Biotech | Oneness Biotech Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

asiaticoside a (2 trials)

salvigenin (2 trials)

Drugs in Phase 2 Trials (5)

centella asiatica (1 trial)

fb704a (2 trials)

fb825 (3 trials)

mb-6 (1 trial)

ms-20 (4 trials)

Drugs in Phase 1 Trials (2)

dbpr110 (1 trial)

ob318 (1 trial)

Drugs in Other Trials (1)

soybean (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Colorectal Neoplasms (Phase 2)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Diabetic Foot (Phase 3)

Eczema (Phase 2)

Foot Ulcer (Phase 3)

Hepatitis (Phase 1)

Hepatitis A (Phase 1)

Hepatitis C (Phase 1)

Hepatitis C, Chronic (Phase 1)

Neoplasms (Phase 1)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 10